Gilead buys Immunomedics in $21bn deal set to strengthen its cancer portfolio 14-Sep-2020 By Jane Byrne In a deal valued at US$21bn, Gilead Sciences is to acquire Immunomedics Inc, a New Jersey headquartered biotech that has been highly focused on breast cancer drug innovation.